NCT05077423 - A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 25, 2022

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2022

Conditions

AML, Childhood

Interventions

DRUG

CD33*CD3 BsAb

CD33xCD3 is a bispecific monoclonal antibody, which specifically targets CD33 on the AML blasts and CD3 on the T cells

Trial Locations (13)

Memorial Sloan Kettering Cancer Center, New York

UPMC Children's Hospital of Pittsburgh, Pittsburgh

Children's Hospital of Philadelphia, Philadelphia

Children's National Hospital, Washington D.C.

Children's of Alabama/University of Alabama at Birmingham, Birmingham

St Jude Children's Research Hospital, Memphis

Cincinnati Children's Hospital Medical Center, Cincinnati

University of Minnesota/Masonic Cancer Center, Minneapolis

Washington University School of Medicine, St Louis

Children's Hospital of Orange County, Orange

UCSF Benioff Children's Hospital, San Francisco

Riley Hospital for Children - Indiana University, Indianapolis

Dana-Farber Cancer Institute, Boston